1. Generics Bulletin
  2. >>Policy & Regulation

BGMA Warns No-Deal Brexit Will Harm Depleted UK Stockpile

As European Governments Brace For Possible Second Wave Of COVID-19

 
• By Akriti Seth

While the UK’s drugs stockpile is depleting due to high demand caused by the coronavirus pandemic, a no-deal Brexit in January 2021 may further harm medicines supply during a possible second wave of COVID-19.

Mask_Pills
The UK Government needs to act quickly to rebuild its drug stockpile • Source: Shutterstock

Warning against a non-negotiated exit from the EU in the midst of the COVID-19 pandemic, Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association, has cautioned that a “no-deal” Brexit could “potentially disrupt supplies of medicines further at the end of the year.”

Currently, the UK is due to end its transition period with the EU on 31 December 2020 after formally leaving...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

Sandoz Scores Regional First With EU Launch Of Autoinjectable Stelara Rival

 
• By Adam Zamecnik

Doubling down on the launch of its Stelara biosimilar Pyzchiva in Europe last year, Sandoz has just released an autoinjectable version of the drug, with the aim to offer a more convenient option for ustekinumab patients.

UK-EU Deal ‘Must Include Medicines, Not Just Sausages,’ Urges Medicines UK

 
• By Urtė Fultinavičiūtė

The UK struck three international agreements in May, but two of them failed to include medicines or provide any benefits for the pharmaceutical sector. Medicines UK warned that protecting medicine supplies should be of the same importance as defense.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Trump-Trimmed FDA Finally Releases A Batch Of PSGs – Back To Business As Usual?

 
• By Urtė Fultinavičiūtė

After half a year of silence, the US FDA has published 48 product-specific guidances for generic development. With critical staff laid off, will the health agency stick to its updated PSG publishing schedule?

More from Generics Bulletin

Shilpa Stumbles On Lenvima Challenge And Faces Wait Until 2036

 
• By Dean Rudge

Generic competition to Eisai’s oral-dose blockbuster cancer therapy Lenvima is set to materialize in the US in 2030 – however, for now, that won’t be from ANDA filer Shilpa Medicare.

The Generics Bulletin Podcast: The Global Generics & Biosimilars Awards 2025

 
• By Dave Wallace and Dean Rudge

With entries now open for the Global Generics & Biosimilars Awards 2025 – which takes place in Frankfurt on Wednesday 29 October – Generics Bulletin’s editors discuss all the key details, including tips for entrants, in our latest podcast.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now